Report #2829837

Received Mar 6, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: CA
Recovered: Unknown
Vaccinated: Dec 11, 2024
Onset: Jan 15, 2025
Days to onset: 35
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	—	—

Symptoms (2)

Extra dose administeredNo adverse event

Symptom narrative

Received One Dose on HEPLISAV B on 12/11/2024, and Then a Dose Engerix on 1/15/2025; Initial report received on 20-Feb-2025. A pharmacist reported that a patient (age, gender, race, ethnicity not provided) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and was given ENGERIX-B as the second dose. No medical history or concomitant medications were reported. On 11-Dec-2024, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot #, expiration date, NDC #, route, and site not available)]. On 15-Jan-2025, 35 days after having been vaccinated with HEPLISAV-B, the patient was given ENGERIX-B (lot #, expiration date, NDC #, route, and site not available). No adverse events were reported. No additional information is available. Company Comment: ?The company assessed the event as non-serious.; Sender's Comments: ? The company assessed the event as non-serious.